cepheid approv better
saturday march cepheid divis receiv approv rapid
test provid result minut compar sever hour exist
technolog qpcr cepheid indic start ship test week
compat instal base genexpert system global us
assum util test could perform annual util
rate impact myriad factor test price releas
kit typic rang importantli advent test provid better
data infect fatal rate fatal rate depend upon accur patient count
one uk research best guess affect wuhan
even though confirm januari wuhan fatal rate
cite higher patient count would lower rate significantli
exampl nucleic acid test capac wuhan start sampl reach
sampl februari wuhan fatal estim low
nation health commiss china estim ex-hubei ex-
wuhan worldomet use cdc data cite fatal rate equal
danah opco fight global pandem diagnost play crucial role
identif monitor ultim treatment diseas current
global pandem highlight import time accur
diagnosi highli infecti diseas proven fatal howev
develop diagnost novel pathogen occur overnight given
develop timelin implic misdiagnosi said
oper compani name cepheid integr
player fight current global pandem
cepheid cepheid lead manufactur molecular diagnost
acquir cepheid market genexpert point-of-car
platform portfolio diagnost test rang infecti diseas
sexual health hospital-associ infect point-of-car platform
genexpert bring high-qual molecular test closer patient enabl
clinician diagnos patient faster initi treatment accordingli
compar send patient sampl lab special equip
personnel test march fda grant emerg use
author xpert xpress sar test pathogen caus
pandem cepheid test enabl detect viru
minut compar current turnaround time hour hour
day due capac constraint cepheid unit place
global nearli unit us
integr acquir
lead manufactur dna/rna oligonucleotid expertis
oligonucleotid short strand dna synthesi critic cdc
develop real-tim rt-pcr test order correctli diagnos patient
show symptom manufactur sell one compon
test primer-prob kit primer kit short strand
dna/rna bind target dna molecul sampl order
amplifi wherea probe also short strand dna/rna label
fluoresc molecul enabl detect target dna strand
march note achiev scale manufactur kit million test
ge biopharma close thursday march feder trade commiss
ftc report approv dhr-buy bn acquisit gener
electr ge-nr bio-pharma busi repres last regulatori approv
need transact close transact set close march
written plenti transact announc last februari link
link link howev view market still underappreci valu
asset acquir reason largest player
bioproduct absolut total revenu rel basi
total revenu estim bn purchas price repres
substanti discount publicli trade peer current valu
base macro analysi peer commentari long-term
guidanc core growth like conserv
visibl given zero visibl
end pandem ultim econom impact assumpt
estim guidanc achiev investor
ultim look current pandem unlik anyth
experienc experi market shock link suggest
estim safe histor life scienc tool shown
abil rapidli recov exogen shock think
particularli appeal shed slowest growth asset dental
ad premier asset bioproduct fastest-grow secular end market
life scienc assum current estim hold trade
ev/ebitda estim approxim turn rang well
peer rang
fair valu reiter fair valu buy rate fv
reach appli multipl ebitda estim
sh deduct estim debt per share guid
earn accret first year ownership life
scienc group typic valu around ev/ebitda expect
bp annual margin expans faster organ growth
million except per share data
impact foreign currenc
total sale
earn jv
management guid cent fx/tariff headwind
